Beyond Glycemic Control: Precision Medicine in Type 2 Diabetes Using Multi-Output Explainable Artificial Intelligence for Personalized SGLT2 and DPP-4 Therapy Selection
Open Access
Abstract
Traditional treatment strategies for Type 2 diabetes (T2D) adopt a “one-size-fits-all” approach, limiting individual effectiveness. This study presents an explainable, data-driven framework for multi-treatment and single-treatment selection of SGLT2 inhibitors (SGLT2-i) and DPP-4 inhibitors (DPP4-i) based on patient-specific health characteristics. Our approach evaluates treatment effectiveness across four outcomes—glycosylated hemoglobin (HbA1c), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and body mass index (BMI)—to enable individualized treatment recommendations. The multi-treatment model, based on multi-output regression, achieved an R2 score of 0.44 and an RMSE of 5.58, identifying benefit subgroups for SGLT2-i and DPP4-i across all outcomes. Integrated with SHapley Additive exPlanations (SHAP) analysis, the model offers insights into the factors influencing treatment effects. The single-treatment selection algorithm achieved an accuracy of 0.47 and an F1 score of 0.46, showing a higher average treatment effect with SGLT2-i on all outcomes, notably in the reduction in HbA1c, LDL, and BMI and a modest increase in HDL. While DPP4-i demonstrated beneficial effects on HbA1c, LDL, and HDL, it was associated with an increase in BMI. These findings highlight the benefits of a multi-faceted, patient-centered precision medicine approach for T2D management, enabling treatment strategies that address individual health needs beyond HbA1c.Keywords
Funding Information
- European Commission (825162)
This publication has 28 references indexed in Scilit:
- Health and economic impact of improved glucose, blood pressure and lipid control among German adults with type 2 diabetes: a modelling studyDiabetologia, 2023
- Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort studyThe Lancet Digital Health, 2022
- Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetesDiabetes & Metabolism, 2021
- Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 UpdateCanadian Journal of Diabetes, 2020
- Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia, 2020
- When metformin is not enough: Pros and cons of SGLT2 and DPP‐4 inhibitors as a second line therapyDiabetes/Metabolism Research and Reviews, 2018
- Healthcare Costs Associated with Change in Body Mass Index in Patients with Type 2 Diabetes Mellitus in SpainApplied Health Economics and Health Policy, 2012
- DPP-4 inhibitorsBest Practice & Research Clinical Endocrinology & Metabolism, 2007
- Random ForestsMachine Learning, 2001
- Multilayer perceptrons for classification and regressionNeurocomputing, 1991